The Center for Science in the Public Interest (CSPI) sent a letter on October 15 to Acting FDA Commissioner Kyle Diamantas, urging the agency to reject votes by its Pharmacy Compounding Advisory Committee (PCAC) that would add six peptides to the 503A bulk drugs list for compounding.
The PCAC voted on July 23–24 to recommend BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for compounding use, despite explicit opposition from FDA career scientists. CSPI’s letter marks the first formal response from a public health organization to those advisory votes and adds institutional pressure on the FDA as it decides whether to act on recommendations its own staff rejected.
CSPI argues that the advisory panel was improperly constituted after HHS reshuffled its membership before the vote, and that none of the six peptides met statutory criteria for safety, effectiveness, or characterization.
What happened
In its letter, CSPI raised concerns about the composition of the PCAC ahead of the July vote. The organization said several new members were reportedly placed on the panel under HHS pressure and had financial ties to peptide businesses. CSPI contends that the panel’s recommendations should not stand given those conflicts and the lack of adequate safety data for the substances in question.
The six peptides at issue — BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon — were recommended for addition to the 503A bulk drugs list despite opposition from FDA career scientists. The PCAC votes are advisory only and do not constitute a final FDA decision.
Why it matters
The FDA now faces a decision with significant implications for compounding pharmacies, telehealth companies offering peptide therapies, and consumers. A decision by the FDA to overrule the panel would be consistent with existing agency policy but would draw criticism from peptide advocates who supported the committee’s votes.
Conversely, if the FDA adopts the panel’s recommendations, it would open a new pathway for mass compounding of substances that have limited human safety data. CSPI’s intervention is notable because it represents the first time a public health organization has formally opposed the PCAC votes, lending additional weight to the concerns already raised by FDA staff.
The affected groups include 503A compounding pharmacies, telehealth companies selling peptide therapies, peptide consumers, and FDA policymakers who must weigh the advisory panel’s recommendations against the opposition raised by the agency’s own scientists.
What to watch next
- Whether the FDA accepts, rejects, or modifies the PCAC’s recommendations for the six peptides.
- Any response from peptide advocacy groups or compounding industry organizations to CSPI’s letter.
- Potential further scrutiny of the PCAC membership changes and conflict-of-interest disclosures.
- Whether additional public health or medical organizations weigh in on the compounding of these substances.
Sources
Industry information only. Not medical or legal advice.
